Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ta/T1”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Large-scale testing (Phase 3)Looking for participantsNCT05024773
What this trial is testing

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Who this might be right for
Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a. 112
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Not applicableStudy completedNCT01180478
What this trial is testing

Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer

Who this might be right for
Bladder Cancer
Clinical Research Office of the Endourological Society 965
Not applicableStudy completedNCT01750970
What this trial is testing

Endoscopic Resection of Bladder Tumors

Who this might be right for
Bladder Tumor
Hopital Foch 68
Post-approval studies (Phase 4)WithdrawnNCT06390111
What this trial is testing

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Who this might be right for
Bladder CancerTa/T1CIS
Ferring Pharmaceuticals
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Large-scale testing (Phase 3)Study completedNCT01920269
What this trial is testing

Intravesical Adjuvant Electromotive Mitomycin-C

Who this might be right for
Bladder Cancer TNM Staging Primary Tumor (T) TaBladder Cancer TNM Staging Primary Tumor (T) T1Bladder Cancer Transitional Cell Grade
University of Rome Tor Vergata 331
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Large-scale testing (Phase 3)UnknownNCT00003725
What this trial is testing

Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
Anthra Pharmaceuticals 300
Not applicableLooking for participantsNCT06026332
What this trial is testing

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Who this might be right for
Bladder Cancer
Ferring Pharmaceuticals 400
Large-scale testing (Phase 3)Study completedNCT00002990
What this trial is testing

Surgery and BCG in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 1,288
Early research (Phase 1)Study completedNCT03258593
What this trial is testing

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Who this might be right for
Urinary Bladder Neoplasms
National Cancer Institute (NCI) 15
Early research (Phase 1)WithdrawnNCT04109092
What this trial is testing

Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Who this might be right for
Urinary Bladder Neoplasms
Eisai Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Large-scale testing (Phase 3)Ended earlyNCT00042887
What this trial is testing

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 58
Testing effectiveness (Phase 2)Looking for participantsNCT07283835
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd. 16
Large-scale testing (Phase 3)Study completedNCT00003779
What this trial is testing

Biological Therapy in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Swiss Cancer Institute 40
Early research (Phase 1)UnknownNCT00959868
What this trial is testing

Treatment of Superficial Bladder Cancer Using OGX-427

Who this might be right for
Bladder Cancer
Vancouver Coastal Health 36
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Testing effectiveness (Phase 2)Study completedNCT04387461
What this trial is testing

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder Cancer
CG Oncology, Inc. 35
Load More Results